Bottom line
SUHAX vs XLV: the short answer
SUHAX (DWS Health and Wellness Fund) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
XLV is cheaper at 0.08% vs 1.34% — a difference of $126 a year per $10,000 invested.
SUHAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
SUHAX vs XLV side by side
| SUHAX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | DWS (Xtrackers) | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.34% | 0.08% |
| Annual cost per $10k | $134 | $8 |
| 10-yr cost on $10k (prospectus) | $2,095 | $103 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.24% | 0.02% |
| 1-yr return | — | +14.5% |
| 5-yr return (annualized) | — | +8.1% |
| 10-yr return (annualized) | — | +9.8% |
| Best quarter | +17.1% | +14.5% |
| Worst quarter | −12.1% | −12.7% |
| Net assets (fund) | $231.8M | $40.6B |
| Number of holdings | 65 | 65 |
| Portfolio turnover | 2% | 2% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SUHAX | XLV | Difference |
|---|---|---|---|
| 2025 | +12.3% | +14.5% | −2.2% |
| 2024 | +3.3% | +2.5% | +0.8% |
| 2023 | +5.1% | +2.0% | +3.2% |
| 2022 | −7.4% | −2.1% | −5.4% |
| 2021 | +15.0% | +25.9% | −10.9% |
| 2020 | +15.1% | +13.3% | +1.9% |
| 2019 | +21.9% | +20.7% | +1.3% |
| 2018 | +3.3% | +6.3% | −3.0% |
| 2017 | +19.0% | +21.7% | −2.7% |
| 2016 | −10.5% | −2.8% | −7.6% |
Source: Fund prospectus bar charts
Holdings overlap
21 of SUHAX's top 25 holdings also appear in XLV's top 25.
| Holding | SUHAX | XLV |
|---|---|---|
| Eli Lilly & Co | 13.85% | 16.51% |
| Johnson & Johnson | 6.19% | 10.64% |
| UnitedHealth Group Inc | 5.73% | 6.57% |
| AbbVie Inc | 4.90% | 7.74% |
| Merck & Co Inc | 4.85% | 5.52% |
| Thermo Fisher Scientific Inc | 3.46% | 3.24% |
| Amgen Inc | 2.88% | 3.40% |
| Gilead Sciences Inc | 2.78% | 2.73% |
| Intuitive Surgical Inc | 2.69% | 2.45% |
| Stryker Corp | 2.61% | 1.89% |
| Vertex Pharmaceuticals Inc | 2.45% | 2.19% |
| Abbott Laboratories | 2.39% | 2.75% |
| Danaher Corp | 2.13% | 2.09% |
| Boston Scientific Corp | 2.10% | 1.10% |
| McKesson Corp | 2.05% | 1.58% |
Source: SEC Form N-PORT
SUHAX top 10
- Eli Lilly & Co — 13.85%
- Johnson & Johnson — 6.19%
- UnitedHealth Group Inc — 5.73%
- AbbVie Inc — 4.90%
- Merck & Co Inc — 4.85%
- AstraZeneca PLC — 3.80%
- Thermo Fisher Scientific Inc — 3.46%
- Novartis AG — 2.90%
- Amgen Inc — 2.88%
- Gilead Sciences Inc — 2.78%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between SUHAX and XLV?
Which is cheaper, SUHAX or XLV?
Should I own both SUHAX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.